President Trump has received a variety of medications that have shown promise in reducing the severity and duration of COVID-19 infections.
Among them is an experimental antibody cocktail that has not received Food and Drug Administration approval.
Today on Wellness Wednesday: how these newly-developed courses of treatment work and what they suggest about the president’s prognosis.
Guests:
- Jody Demo-Hodgins, director of children’s division, NAMI Ohio
- Lisa Gill, health and medicine investigative reporter, Consumer Reports
- Dr. Joe Gastaldo, medical director, OhioHealth
If you have a disability and experience difficulty accessing this content request an accommodation.
